A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449.

Trial Profile

A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Medulloblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Mar 2012 Actual patient number changed from 13 to 21 as reported by ClinicalTrials.gov.
    • 22 Jun 2011 Planned end date changed from 1 Jan 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 06 Jun 2010 Status changed from recruiting to completed, based on information reported in a St. Jude Children's Research Hospital media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top